"USE OF A SPECIFIC ANTAGONIST OF 5HT ~ 2 ~ RECEPTORS FOR THE PREPARATION OF USEFUL DRUGS IN THE TREATMENT OF SLEEP APNEA SYNDROME" . The invention relates to the use of a specific 5HT ~ 2 ~ receptor antagonist for the preparation of medicaments useful in the treatment of sleep apnea syn...
本发明涉及一种高选择性5羟色胺5HT2C受体激动剂WAY163909的新用途.高选择性5羟色胺5HT2C受体激动剂WAY163909的分子式为C14H18N2,分子量为214.30600,白色粉末,水溶性好.所述高选择性5羟色胺5HT2C受体激动剂WAY163909在制备抑制吗啡等阿片类物质成瘾和戒断反应的药物中的应用;或在制备抑制吗啡类物质成瘾和戒断...
The present invention relates to the use of a specific 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of the sleep apnea syndrome. Further disclosed is also a method for the treatment of sleep obstructive apnea-hypoapnea syndrome, which method comprises ...
Receptor specificity of the 5HT, receptor antagonist, LY53857.Drug Dev Res 1985;5:313-21.Cohen ML, Colbert W, Wittenauer LA (1985) Receptor specificity of the 5HT 2 receptor antagonist, LY 53857. Drug Dev Res 5:313–321Cohen ML, Colbert W, Wittenauer LA (1985a) Receptor specificity ...
Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease. Satomura K,Takase B,Hamabe A,et al. Clinical Cardiology . 2002Satomura, K., Takase, B., Hamabe, A., Ashida, K., Hosaka, H., Ohsuzu, F., Kurita, A., 2002. Sarpog...
doi:10.1016/S0268-9499(96)80246-3ELSEVIERFibrinolysis
The present invention relates to a combination of a 5HT2 receptor antagonist having the following general formula (I) or Ia, in which R18 is a C1-C12 alkyl, phenyl or phenyl (C1-C6 alkyl) group, wherein the phenyl group is optionally substituted with a C1-C6 alkoxy, a halogen atom ...
This effect was slightly more pronounced when measured with an antagonist ligand ([H]mesulergine) compared to measurements with an agonist ligand ([I]DOI). The up-regulation was most evident 24 hours after the last dose and disappeared thereafter rather rapidly. Chronic fluoxetine treatment also ...
The residues C-alpha side-chain in active site strongly interacts (hydrogen bonds) with bound agonist (100% interaction: ASP135), known antagonist (95%:ASP135), and LAS 52115629 (100%:ASP135). The R gyr for receptor-ligand complex, LAS 52115629 (25.68), lies close to bound agonist-...
The invention concerns the use of an antagonist of serotonin specific of the 5HT2 receptor or of an agonist of serotonin specific of the 5HT1D receptor in a cosmetic composition or for preparing a dermatological composition for treating sensitive skin. It concerns in particular the use of an ...